Is it the end of the road for abatacept treatment in Sjögren's syndrome?

Benjamin Fisher

Inflammation and Ageing

Research output: Contribution to journal › Comment/debate

1 Citation (Scopus)

290 Downloads (Pure)

Original language	English
Pages (from-to)	e125-e126
Journal	The Lancet Rheumatology
Volume	2
Issue number	3
DOIs	https://doi.org/10.1016/S2665-9913(20)30002-3
Publication status	Published - 31 Jan 2020

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.1016/S2665-9913(20)30002-3Licence: None: All rights reserved

Fisher_End_of_the_road_for_abatacept_in_Sjögren’s_syndrome?_Lancet_Rheumatology_2020Accepted author manuscript, 144 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30002-3/fulltextLicence: None: All rights reserved

Cite this

@article{4d60c94462ed429a8bce1b40a99445e6,

title = "Is it the end of the road for abatacept treatment in Sj{\"o}gren's syndrome?",

author = "Benjamin Fisher",

year = "2020",

month = jan,

day = "31",

doi = "10.1016/S2665-9913(20)30002-3",

language = "English",

volume = "2",

pages = "e125--e126",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Is it the end of the road for abatacept treatment in Sjögren's syndrome?

AU - Fisher, Benjamin

PY - 2020/1/31

Y1 - 2020/1/31

UR - https://www.scopus.com/pages/publications/85079890691

U2 - 10.1016/S2665-9913(20)30002-3

DO - 10.1016/S2665-9913(20)30002-3

M3 - Comment/debate

SN - 2665-9913

VL - 2

SP - e125-e126

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 3

ER -